Effect of an Infant Formula With Synbiotics in Infants Born Via Caesarean Section

Exclusion Criteria

• •Intensive care prior to or at Baseline Visit
• •UV-treatment of jaundice and clinical significant jaundice prior to Baseline Visit (according to investigator opinion)
• •Known immune deficiency
• •Serious acquired or congenital diseases, chromosomal anomalies (if known)
• •Serious pre-natal and/or serious post-natal disease before enrolment (per investigator's medical diagnosis)
• •Infants or mothers under antibiotic treatment before Baseline Visit (only for vaginally born and breastfed infants) or at Baseline Visit (all groups)
• •Infants requiring infant formula intake other than those specified in the protocol (formula for special medical purposes (FSMP), formula with hydrolyzed protein (allergy risk)
• •Infant's supplementation or formula intake, which contains probiotics, prebiotics, dietary fibres or synbiotics before and during study
• •Feeding difficulties or formula intolerance according to investigator's opinion
• •Currently participating or having participated in another clinical trial since birth
• •Reason to presume that the infant's parent(s)/LAR(s) are unable to meet the study plan requirements, such as drug/alcohol abuse, psychological or linguistic incapability, chronic or mental diseases
• •Infants born to mothers with medical conditions that require prescription medication (coagulation abnormalities, if acetylsalicylic acid was not stopped at 35 weeks GA according to guidelines, mothers treated with Methyldopa, ACE inhibitors, breastfeeding mothers treated with L-thyroxine, diabetic mothers, epileptic mothers)
• •Any smoking, drug or alcohol intake by the mother during the last two trimesters of pregnancy
• •Mother's weight gain \>18 kg during pregnancy